A Phase II clinical trial showed good response in combination chemotherapy with gemcitabine for advanced pancreatic cancer [REF].
In 2010, a Phase III trial for previously treated metastatic renal cell carcinoma (mRCC) showed significantly extended progression-free survival when compared to sorafenib [REF].